Maine Nurse Practitioner Loses DEA Registration Rights
Published Date: 6/10/2026
Notice
Summary
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
DEA registration revoked for Vermillion
Ashley Vermillion, N.P., had her DEA Certificate of Registration No. MV750134 revoked, so she cannot prescribe, dispense, or otherwise handle controlled substances under her DEA registration. The agency found her Maine nursing license expired on July 8, 2025, and the revocation is effective July 10, 2026.
Pending and future Maine applications denied
The Order also denies any pending applications of Ashley Vermillion, N.P., to renew or modify her DEA registration and denies any other pending application for additional registration in Maine. That denial is issued along with the revocation and is effective July 10, 2026.
Right to seek reconsideration within 15 days
Ashley Vermillion may file a properly supported motion for reconsideration of the factual finding that her Maine nursing license is expired. Any such motion and response must be filed and served by email within fifteen calendar days of the date of this Order.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
2026-20757, Schedules of Controlled Substances; Removal of Exemption Status for Inactive Butalbital Products
The DEA is removing the special exemption for certain inactive butalbital prescription products that are no longer made or sold. Starting November 9, 2026, these products won’t be treated as exempt under drug laws anymore, but active products stay the same. This change mainly affects drug companies and pharmacies handling these old products, with no new costs for active medicines.
Previous / Next Documents
Previous: 2026-11571, Notice of Availability of Designation of Chinese Military Companies
The U.S. Department of Defense just named several Chinese companies as military-linked and operating in the U.S. This means these companies, like Qihoo 360 and CH UAV, are officially flagged for their ties to China’s military. The list updates every year through 2030, so businesses and investors should watch out for potential restrictions or impacts on deals involving these companies.
Next: 2026-11573, Certain Smart Devices; Notice of Institution of Investigation
Cerence Operating Company has asked the U.S. International Trade Commission to investigate certain smart devices that might be using their patented technology without permission. This could lead to restrictions on importing and selling these devices in the U.S., possibly affecting companies and shoppers soon. The investigation started on June 5, 2026, and could bring big changes to the smart device market and money flow.